IRulya Therapeutics Inc. Common Stock
IRLA
32 hedge funds and large institutions have $6.96M invested in IRulya Therapeutics Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
1,875% more call options, than puts
Call options by funds: $79K | Put options by funds: $4K
0.28% more ownership
Funds ownership: 11.61% → 11.89% (+0.28%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
3% less funds holding
Funds holding: 33 → 32 (-1)
27% less capital invested
Capital invested by funds: $9.55M → $6.96M (-$2.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
IEQ Capital
Foster City,
California
|
+$1.23M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$282K |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
+$81.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$61.7K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$55.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$156K |
| 2 |
SC
Shay Capital
New York
|
-$141K |
| 3 |
Morgan Stanley
New York
|
-$35.4K |
| 4 |
Renaissance Technologies
New York
|
-$35.1K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$28.7K |
IRLA Hedge Fund Activity: Q1 2025 in Review
32 of the 7,477 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q1 2025, worth a combined $6.96M — down 27% from $9.55M a quarter earlier.
Fund positioning in IRLA was balanced in Q1 2025: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was IEQ Capital, opening a new position worth an estimated $1.23M. The largest seller was BlackRock, cutting an estimated $156K.
- 32 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q1 2025, down from 33 in Q4 2024.
- Funds reported $6.96M of IRulya Therapeutics Inc. Common Stock stock for Q1 2025, down 27% quarter-over-quarter.
- 6 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q1 2025 and 6 closed out, a net change of 0 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q1 2025 was IEQ Capital, an estimated $1.23M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q1 2025 was BlackRock, an estimated $156K sold.
Based on aggregated 13F filings for Q1 2025.